Pfizer and BioNTech begin clinical trial for omicron-specific vaccine
CNN, January 25, 2022
Pfizer and BioNTech have begun a clinical trial for their omicron-specific COVID-19 vaccine candidate. For background, CNN also reported that a new preprint lab study suggests that antibodies against the omicron coronavirus variant remain robust four months after a third dose of the Pfizer/BioNTech vaccine. “Additional real world effectiveness data and laboratory investigations will further inform the duration of protection, potential need for an additional dose at a later time, and whether an Omicron modified vaccine is required,” said the study from researchers at the University of Texas Medical Branch, Pfizer and BioNTech. Many national and international news outlets shared the CNN story.